Top cited articles

Acceptance rate

59%

Time to first decision

26 days*

Time from acceptance to publication

15 days*

Impact Factor

4.235

Citescore

5.1

Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review
Strand, Vibeke; Simon, Lee S.; Meara, Alexa Simon; Touma, Zahi
10.1136/lupus-2019-000373

Associations of metabolic syndrome in SLE
Apostolopoulos, Diane; Vincent, Fabien; Hoi, Alberta; Morand, Eric
10.1136/lupus-2020-000436

Targeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lpr mice
Fortner, Karen A.; Blanco, Luz P.; Buskiewicz, Iwona. et al
10.1136/lupus-2020-000387

Effects of metformin on disease flares in patients with systemic lupus erythematosus: post hoc analyses from two randomised trials
Sun, Fangfang; Geng, Shikai; Wang, Haiting. et al
10.1136/lupus-2020-000429

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
Tummala, Raj; Abreu, Gabriel; Pineda, Lilia. et al
10.1136/lupus-2020-000464

High-risk coronary plaque in SLE: low-attenuation non-calcified coronary plaque and positive remodelling index
Stojan, George; Li, Jessica; Budoff, Matthew. et al
10.1136/lupus-2020-000409

Living with systemic lupus erythematosus in 2020: a European patient survey
Cornet, Alain; Andersen, Jeanette; Myllys, Kirsi. et al
10.1136/lupus-2020-000469

Combining C reactive protein and serum albumin to predict 90-day mortality in systemic lupus erythematosus with serious community-acquired infections
He, Shuangjun; Tang, Chao; Yu, Jie. et al
10.1136/lupus-2021-000505

Atherosclerosis in SLE: a potential role for serum parathormone levels
Giannelou, Mayra; Skarlis, Charalampos; Stamouli, Aikaterini. et al
10.1136/lupus-2020-000393

Finding lupus in the ANA haystack
Olsen, Nancy J.; Karp, David R.
10.1136/lupus-2020-000384

2021 DORIS definition of remission in SLE: final recommendations from an international task force
van Vollenhoven, Ronald F.; Bertsias, George; Doria, Andrea. et al
10.1136/lupus-2021-000538

Infection hospitalisation in systemic lupus in Sweden
Simard, Julia F.; Rossides, Marios; Gunnarsson, Iva. et al
10.1136/lupus-2021-000510

Apolipoprotein L1 risk genotypes in Ghanaian patients with systemic lupus erythematosus: a prospective cohort study
Blazer, Ashira; Dey, Ida Dzifa; Nwaukoni, Janet. et al
10.1136/lupus-2020-000460

Outcomes of pregnancy and associated factors in sub-Saharan African women with systemic lupus erythematosus: a scoping review
Essouma, Mickael; Nkeck, Jan Rene; Motolouze, Kodoume. et al
10.1136/lupus-2020-000400

SARS-CoV-2 vaccines in patients with SLE
Tang, Wei; Askanase, Anca D.; Khalili, Leila; Merrill, Joan T.
10.1136/lupus-2021-000479

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways
Doerner, Thomas; Tanaka, Yoshiya; Petri, Michelle A. et al
10.1136/lupus-2020-000424

Impact of COVID-19 pandemic on SLE: beyond the risk of infection
Horisberger, Alice; Moi, Laura; Ribi, Camillo; Comte, Denis
10.1136/lupus-2020-000408

Prediction of prognosis and renal outcome in lupus nephritis
Parodis, Ioannis; Tamirou, Farah; Houssiau, Frederic A.
10.1136/lupus-2020-000389

Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
Ajeganova, Sofia; Gustafsson, Thomas; Lindberg, Linnea. et al
10.1136/lupus-2019-000362

High disease activity status suggests more severe disease and damage accrual in systemic lupus erythematosus
Koelmeyer, Rachel; Tri Nim, Hieu; Nikpour, Mandana. et al
10.1136/lupus-2019-000372